HIV/MTB双重感染合并抗结核药物性肝损伤患者的临床特征

肝脏 ›› 2023, Vol. 28 ›› Issue (4): 483-486.

HIV/MTB双重感染合并抗结核药物性肝损伤患者的临床特征

阮军, 尹恒, 寇国先, 杨成彬

621000 电子科技大学医学院附属绵阳医院·绵阳市中心医院感染科(阮军,寇国先),肾病科(尹恒); 凉山州布拖县人民医院感染科(杨成彬)

收稿日期:2022-06-06 出版日期:2023-04-30 发布日期:2023-08-29
通讯作者: 尹恒,Email:45864791@qq.com
基金资助:
中国肝炎防治基金会-天晴肝病研究基金资助课题(TQGB20200007)

Clinical characteristics of HIV-MTB co-infected patients combined with anti-tuberculosis drug-induced liver injury

RUAN Jun¹, YIN Heng², KOU Guo-xian¹, YANG cheng-bin³

1. Department of Infectious diseases, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Sichuan 621000,China;
2. Department of Nephrology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China,Sichuan 621000,China;
2. Department of Infectious diseases, Butuo People's Hospital of Liangshan Prefecture, Sichuan 615350,China

Received:2022-06-06 Online:2023-04-30 Published:2023-08-29
Contact: YIN Heng, Email: 45864791@qq.com

摘要/Abstract

摘要： 目的探讨人类免疫缺陷病毒/结核分枝杆菌(HIV/MTB)双重感染合并抗结核药物性肝损伤(ATB-DILI)患者的临床特征。方法回顾性分析2017年10月至2019年10月凉山州布拖县人民医院189例HIV/MTB双重感染合并ATB-DILI患者的临床资料。结果 189例患者中,111例(58.7%)为中青年已婚女性,149例(78.8%)来自乡村地区,135例(71.4%)经异性性接触传播感染HIV。ATB-DILI临床分型有肝细胞损伤型105例(55.6%),胆汁淤积型61例(32.3%)和混合型23例(12.1%)。常见临床表现为乏力、食欲减退117例(61.9%),恶心、厌油95例(50.2%),黄疸83例(43.9%),皮肤瘙痒71例(37.6%)等。肝细胞损伤型患者ALT和ALP分别为(324.5±127.1)U/L、(142.7±53.5)U/L,胆汁淤积型分别为(217.3±86.4)U/L、(395.4±156.3)U/L,混合型分别为(243.9±95.3)U/L、(272.5±101.4)U/L。CD4⁺T淋巴细胞计数＜200个/μL 80例(42.3%),尤其是肝细胞损伤型降低最显著。腹部影像学检查变化多样,缺乏特异性。结论 HIV/MTB双重感染合并ATB-DILI临床表现多样,以消化系统损伤为主,多数患者预后良好。

关键词: 人类免疫缺陷病毒, 结核分枝杆菌, 抗结核药物性肝损伤, 临床特征

Abstract: Objective To analyze the clinical characteristics of anti-tuberculosis drug-induced liver injury(ATB-DILI) patients co-infected with human immunodeficiency virus and mycobacterium tuberculosis(HIV-MTB). Methods The clinical data of 189 cases admitted to the people's hospital of Butuo county in Liangshan prefecture from October 2017 to October 2019 were retrospectively analyzed. Results Among 189 enrolled subjects, 111 cases(58.7%) were young and middle-aged married women, 149 cases(78.8%) were from rural areas, and 135 patients(71.4%) were infected with HIV through heterosexual contact. Most cases of DILI presented with hepatocellular injury(55.6%, Group A), followed by cholecystitis(32.3%, Group B) and mixed type(12.1%, Group C). Patients commonly presented with fatigue and appetit(61.9%), nausea and oil aversio(50.2%), jaundice43.9%), skin itchings(37.6%) and so on. In liver function examination, the ALT level of Group A was higher than that of Group B and Group C[(324.5±127.1)U/L, vs (217.3±86.4)U/L, (243.9±95.3)U/L)]. The ALP level of Group B was higher than that of Group A and Group C[(395.4±156.3)U/L vs (142.7±53.5)U/L, (272.5±101.4)U/L. The CD4+T lymphocyte count(＜200/μL) decreased significantly in 80 cases(42.3%), especially in Group A(175.9±71.3)/μL The abdominal imaging examinations in the three groups varied with no specificity. Conclusion The clinical manifestations of HIV-MTB co-infected patients combined with ATB-DILI are various, mainly presented with digestive system injury, and the prognosis of most patients is good. However, the early screening and intervention of ATB-DILI population in Liangshan prefecture still need to be strengthened.

Key words: Human immunodeficiency virus, Mycobacterium tuberculosis, Anti-tuberculosis drug-induced liver injury, Clinical characteristics

阮军, 尹恒, 寇国先, 杨成彬. HIV/MTB双重感染合并抗结核药物性肝损伤患者的临床特征[J]. 肝脏, 2023, 28(4): 483-486.

RUAN Jun, YIN Heng, KOU Guo-xian, YANG cheng-bin. Clinical characteristics of HIV-MTB co-infected patients combined with anti-tuberculosis drug-induced liver injury[J]. Chinese Hepatolgy, 2023, 28(4): 483-486.

参考文献

[1] 中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心.中国艾滋病诊疗指南(2018年版).中华内科杂志,2018,57:867-884.
[2] 中国性病艾滋病防治协会HIV合并结核病专业委员会.人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识.中华传染病杂志,2022,40:6-19.
[3] 中华医学会结核病学分会.抗结核药物性肝损伤诊治指南(2019年版).中华结核和呼吸杂志,2019,42:343-356.
[4] 中华医学会肝脏病学分会药物性肝病学组.药物性肝损伤诊治指南.临床肝胆病杂志,2015,31:1752-1769.
[5] World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization,2021.
[6] Gao J, Zheng P, Fu H. Prevalence of TB/HIV co-infection in countries expect China: a systematic review and meta-analysis. PLoS One,2013,8: e64915.
[7] Galgalo T, Dalal S, Cain KP, et al. Tuberculosis risk among staff of a large public hospital in Kenya. Int J Tuberc Lung Dis,2008,12:949-954.
[8] Tadege M. Time to death predictors of HIV/AIDS infected patients on antiretroviral therapy in Ethioopia. BMC, Res Notes,2018,11:761.
[9] Malnick S, Maor Y, Melzer E, et al. Severe hepatocytotoxicity linked to denosumab. Eur Rev Med Pharmacol Sci,2017,21:78-85.
[10] Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced Liver injury in Mainland China. Gastroenterology,2019,156:2230-2241.
[11] 吴念宁,陈万,邹俊,等.HIV/TB病人抗结核治疗强化期发生药物性肝炎的研究.中国艾滋病性病,2014,20:13-16.
[12] 谢祎,孙昕.结核病与艾滋病双重感染的流行现状与研究进展.中华医院感染学杂志,2019,29:3036-3040.
[13] 刘芳,臧珊珊,刘永梅,等.抗结核治疗致肺结核患者药物性肝损伤的风险因素分析.解放军医药杂志,2019,31:56-59.
[14] 刘覃俊,余晓梅.超声影像学检查在药物性肝损伤诊断与治疗中的应用价值.胃肠病学和肝病学杂志,2017,26:303-306.
[15] 宋娟,闫晓君,张迎.药物性肝损伤的临床特点及影像学特征分析.中华灾害救援医学,2019,7:678-681.
[16] 姜雪,赵燕,吉克春农,马烨,等.2005-2015年凉山州彝族自治州艾滋病抗病毒治疗患者生存时间及相关因素分析.中华预防医学杂志,2020,54:1237-1242.
[17] 李京,李婷,李运葵,等.艾滋病高流行地区TB/HIV双重感染住院患者流行病学特征及影响因素分析.中国艾滋病性病,2020,26:530-533.
[18] 杨松,郭建琼,严晓峰.抗结核药物性肝损伤发生机制的研究进展.中华结核和呼吸杂志,2019,42:378-381.